{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:16:47Z","timestamp":1782253007308,"version":"3.54.5"},"reference-count":115,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":672,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1111\/apt.12538","type":"journal-article","created":{"date-parts":[[2013,10,29]],"date-time":"2013-10-29T10:00:56Z","timestamp":1383040856000},"page":"35-46","source":"Crossref","is-referenced-by-count":49,"title":["Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease"],"prefix":"10.1111","volume":"39","author":[{"given":"C.","family":"Pipili","sequence":"first","affiliation":[{"name":"Department of Nephrology; Laiki Merimna; Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cholongitas","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine; Medical School of Aristotle University; Hippokration General Hospital; Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Papatheodoridis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology; Athens University Medical School; Laiko General Hospital of Athens; Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,10,29]]},"reference":[{"key":"10.1111\/apt.12538-BIB0001|apt12538-cit-0001","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1111\/apt.12538-BIB0002|apt12538-cit-0002","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/liv.12054","article-title":"Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?","volume":"33","author":"Papatheodoridis","year":"2013","journal-title":"Liver Int"},{"key":"10.1111\/apt.12538-BIB0003|apt12538-cit-0003","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","journal-title":"J Hepatol"},{"key":"10.1111\/apt.12538-BIB0004|apt12538-cit-0004","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1473-3099(07)70264-5","article-title":"Therapeutic strategies in the management of patients with chronic hepatitis B virus infection","volume":"8","author":"Papatheodoridis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/apt.12538-BIB0005|apt12538-cit-0005","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1572-0241.2002.05819.x","article-title":"Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/apt.12538-BIB0006|apt12538-cit-0006","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/apt.12538-BIB0007|apt12538-cit-0007","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/apt.12538-BIB0008|apt12538-cit-0008","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/apt.12538-BIB0009|apt12538-cit-0009","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/apt.12538-BIB0010|apt12538-cit-0010","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/hep.510290321","article-title":"Efficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B Lamivudine Precore Mutant Study Group","volume":"29","author":"Tassopoulos","year":"1999","journal-title":"Hepatology"},{"key":"10.1111\/apt.12538-BIB0011|apt12538-cit-0011","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.12538-BIB0012|apt12538-cit-0012","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/jhep.2002.33894","article-title":"Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease","volume":"36","author":"Papatheodoridis","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/apt.12538-BIB0013|apt12538-cit-0013","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/apt.12538-BIB0014|apt12538-cit-0014","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/apt.12538-BIB0015|apt12538-cit-0015","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/apt.12538-BIB0016|apt12538-cit-0016","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","article-title":"Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B","volume":"126","author":"Peters","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.12538-BIB0017|apt12538-cit-0017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2036.2003.01810.x","article-title":"Review article: current management of chronic hepatitis B","volume":"19","author":"Papatheodoridis","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/apt.12538-BIB0018|apt12538-cit-0018","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5\u00a0years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.12538-BIB0019|apt12538-cit-0019","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl.","key":"10.1111\/apt.12538-BIB0020|apt12538-cit-0020","first-page":"1044A","article-title":"Renal function is improved for chronic hepatitis B (CHB) patients treated with telbivudine","volume":"54","author":"Gane","year":"2011","journal-title":"Hepatology"},{"key":"10.1111\/apt.12538-BIB0021|apt12538-cit-0021","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/jvh.12025","article-title":"Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B","volume":"20","author":"Wang","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1111\/apt.12538-BIB0022|apt12538-cit-0022","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5\u00a0years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1111\/apt.12538-BIB0023|apt12538-cit-0023","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5\u00a0years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/apt.12538-BIB0024|apt12538-cit-0024","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"issue":"(Suppl.)","key":"10.1111\/apt.12538-BIB0025|apt12538-cit-0025","first-page":"374A","article-title":"Six years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance","volume":"56","author":"Marcellin","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1111\/apt.12538-BIB0026|apt12538-cit-0026","first-page":"389A","article-title":"Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-na\u00efve patients with chronic hepatitis B followed for 3\u00a0years in a multicenter European study","volume":"56","author":"Lampertico","year":"2012","journal-title":"Hepatology"},{"key":"10.1111\/apt.12538-BIB0027|apt12538-cit-0027","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"Bommel","year":"2010","journal-title":"Hepatology"},{"key":"10.1111\/apt.12538-BIB0028|apt12538-cit-0028","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cgh.2012.04.008","article-title":"Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B","volume":"10","author":"Gish","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/apt.12538-BIB0029|apt12538-cit-0029","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jhep.2011.03.030","article-title":"Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B","volume":"55","author":"Mauss","year":"2011","journal-title":"J Hepatol"},{"key":"10.1111\/apt.12538-BIB0030|apt12538-cit-0030","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","article-title":"Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis","volume":"19","author":"Chan","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1111\/apt.12538-BIB0031|apt12538-cit-0031","doi-asserted-by":"crossref","first-page":"e54279","DOI":"10.1371\/journal.pone.0054279","article-title":"52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B","volume":"8","author":"Piratvisuth","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1111\/apt.12538-BIB0032|apt12538-cit-0032","doi-asserted-by":"crossref","DOI":"10.1007\/s12664-013-0325-2","article-title":"Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection","author":"Amarapurkar","year":"2013","journal-title":"Indian J Gastroenterol"},{"key":"10.1111\/apt.12538-BIB0033|apt12538-cit-0033","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1081\/NCN-100002341","article-title":"Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs","volume":"20","author":"Cihlar","year":"2001","journal-title":"Nucleosides, Nucleotides Nucleic Acids"},{"key":"10.1111\/apt.12538-BIB0034|apt12538-cit-0034","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1586\/14787210.2.4.475","article-title":"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection","volume":"2","author":"Hadziyannis","year":"2004","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1111\/apt.12538-BIB0035|apt12538-cit-0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00000441-200306000-00006","article-title":"Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity","volume":"325","author":"Perazella","year":"2003","journal-title":"Am J Med Sci"},{"key":"10.1111\/apt.12538-BIB0036|apt12538-cit-0036","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.23044","article-title":"Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil","volume":"50","author":"Ha","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/apt.12538-BIB0037|apt12538-cit-0037","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1111\/ctr.12109","article-title":"Adefovir treatment for chronic hepatitis B in heart transplant recipients","volume":"27","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1111\/apt.12538-BIB0038|apt12538-cit-0038","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1365-2036.2012.05093.x","article-title":"Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B","volume":"35","author":"Gara","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/apt.12538-BIB0039|apt12538-cit-0039","first-page":"179","article-title":"Proximal tubular renal dysfunction or damage in HIV-infected patients","volume":"14","author":"Palacio","year":"2012","journal-title":"AIDS Rev"},{"key":"10.1111\/apt.12538-BIB0040|apt12538-cit-0040","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence","volume":"57","author":"Hall","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/apt.12538-BIB0041|apt12538-cit-0041","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1086\/499048","article-title":"Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions","volume":"42","author":"Zimmermann","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/apt.12538-BIB0042|apt12538-cit-0042","first-page":"354908","article-title":"Tenofovir nephrotoxicity: 2011 update","volume":"2011","author":"Fernandez-Fernandez","year":"2011","journal-title":"AIDS Res Treat"},{"key":"10.1111\/apt.12538-BIB0043|apt12538-cit-0043","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MCG.0b013e3181e12ed3","article-title":"Hypophosphataemic osteomalacia in patients on adefovir dipivoxil","volume":"45","author":"Girgis","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/apt.12538-BIB0044|apt12538-cit-0044","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/j.1478-3231.2011.02616.x","article-title":"Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients","volume":"31","author":"Manolakopoulos","year":"2011","journal-title":"Liver Int"},{"issue":"Suppl.","key":"10.1111\/apt.12538-BIB0045|apt12538-cit-0045","first-page":"1011A","article-title":"Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis","volume":"54","author":"Marcellin","year":"2011","journal-title":"Hepatology"},{"key":"10.1111\/apt.12538-BIB0046|apt12538-cit-0046","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/ndt\/gfh658","article-title":"Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study","volume":"20","author":"Izzedine","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/apt.12538-BIB0047|apt12538-cit-0047","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/cid\/cis937","article-title":"Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10\u00a0years of follow-up","volume":"56","author":"Laprise","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1111\/apt.12538-BIB0048|apt12538-cit-0048","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1399-3062.2012.00741.x","article-title":"Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation","volume":"14","author":"Cholongitas","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1111\/apt.12538-BIB0049|apt12538-cit-0049","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.md.0000180792.80212.5e","article-title":"Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients","volume":"84","author":"Guillevin","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/apt.12538-BIB0050|apt12538-cit-0050","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000077065","article-title":"Hepatitis B virus-associated nephropathy","volume":"24","author":"Bhimma","year":"2004","journal-title":"Am J Nephrol"},{"key":"10.1111\/apt.12538-BIB0051|apt12538-cit-0051","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3748\/wjg.v9.i9.2004","article-title":"Role of hepatitis B virus infection in pathogenesis of IgA nephropathy","volume":"9","author":"Wang","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.1111\/apt.12538-BIB0052|apt12538-cit-0052","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5414\/CNP65380","article-title":"Hepatitis B infection as a possible cause of focal segmental glomerulosclerosis (FSGS)","volume":"65","author":"Herberth","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1111\/apt.12538-BIB0053|apt12538-cit-0053","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0929-6646(08)60054-6","article-title":"Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy","volume":"106","author":"Chuang","year":"2007","journal-title":"J Formos Med Assoc"},{"key":"10.1111\/apt.12538-BIB0054|apt12538-cit-0054","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1155\/2005\/378587","article-title":"Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection","volume":"19","author":"Gan","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1111\/apt.12538-BIB0055|apt12538-cit-0055","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5414\/CNP70069","article-title":"Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis","volume":"70","author":"Mesquita","year":"2008","journal-title":"Clin Nephrol"},{"key":"10.1111\/apt.12538-BIB0056|apt12538-cit-0056","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5414\/CNP65053","article-title":"Successful treatment of hepatitis B virus-associated membranous nephropathy with lamivudine","volume":"65","author":"Okuse","year":"2006","journal-title":"Clin Nephrol"},{"issue":"Suppl. 2","key":"10.1111\/apt.12538-BIB0057|apt12538-cit-0057","first-page":"S151","article-title":"Hepatitis-B virus-associated nephropathies in adults: a clinical study in Thailand","volume":"89","author":"Panomsak","year":"2006","journal-title":"J Med Assoc Thai"},{"key":"10.1111\/apt.12538-BIB0058|apt12538-cit-0058","first-page":"433","article-title":"Hepatitis B complicated focal segmental glomerulosclerosis","volume":"18","author":"Sakallioglu","year":"2005","journal-title":"J Nephrol"},{"key":"10.1111\/apt.12538-BIB0059|apt12538-cit-0059","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3904\/kjim.2012.27.4.411","article-title":"Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains","volume":"27","author":"Sun","year":"2012","journal-title":"Korean J Intern Med"},{"key":"10.1111\/apt.12538-BIB0060|apt12538-cit-0060","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/j.1523-1755.2005.00591.x","article-title":"Lamivudine in hepatitis B-associated membranous nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"key":"10.1111\/apt.12538-BIB0061|apt12538-cit-0061","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5414\/CNP65211","article-title":"Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy","volume":"65","author":"Wen","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1111\/apt.12538-BIB0062|apt12538-cit-0062","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1440-1797.2009.01165.x","article-title":"Hepatitis B virus-related membranous nephropathy treated with entecavir","volume":"15","author":"Ikee","year":"2010","journal-title":"Nephrology (Carlton)"},{"key":"10.1111\/apt.12538-BIB0063|apt12538-cit-0063","first-page":"2264","article-title":"Entecavir combined steroid therapy of clinical manifestations of nephrotic syndrome in HBV-GN","volume":"11","author":"Liu","year":"2008","journal-title":"J Clin Res"},{"key":"10.1111\/apt.12538-BIB0064|apt12538-cit-0064","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/ndt\/gfq600","article-title":"Focal segmental glomerulosclerosis as a complication of hepatitis B virus infection","volume":"26","author":"Sakai","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/apt.12538-BIB0065|apt12538-cit-0065","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.clinre.2012.03.033","article-title":"Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy","volume":"36","author":"Yang","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1111\/apt.12538-BIB0066|apt12538-cit-0066","first-page":"A","article-title":"Telbivudine treatment of chronic hepatitis B patients complicated with hepatitis B virus associated glomerulonephritis","author":"Yan","year":"2013","journal-title":"APASL"},{"key":"10.1111\/apt.12538-BIB0067|apt12538-cit-0067","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1665-2681(19)31565-0","article-title":"The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: a systematic review and meta-analysis","volume":"10","author":"Yi","year":"2011","journal-title":"Ann Hepatol"},{"key":"10.1111\/apt.12538-BIB0068|apt12538-cit-0068","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3748\/wjg.v18.i8.821","article-title":"Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis","volume":"18","author":"Zheng","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1111\/apt.12538-BIB0069|apt12538-cit-0069","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/039139880803100503","article-title":"Hepatitis B virus infection in the dialysis population: current perspectives","volume":"31","author":"Fabrizi","year":"2008","journal-title":"Int J Artif Organs"},{"key":"10.1111\/apt.12538-BIB0070|apt12538-cit-0070","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1525-139X.2008.00437.x","article-title":"Hepatitis B virus infection and the dialysis patient","volume":"21","author":"Fabrizi","year":"2008","journal-title":"Semin Dial"},{"key":"10.1111\/apt.12538-BIB0071|apt12538-cit-0071","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(81)92679-9","article-title":"Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients","volume":"1","author":"Crosnier","year":"1981","journal-title":"Lancet"},{"key":"10.1111\/apt.12538-BIB0072|apt12538-cit-0072","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1001\/jama.1991.03460200059035","article-title":"Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel","volume":"265","author":"Nagafuchi","year":"1991","journal-title":"JAMA"},{"key":"10.1111\/apt.12538-BIB0073|apt12538-cit-0073","first-page":"1369","article-title":"Effects of interleukin-2 on hepatitis B vaccination in uraemic patients","volume":"344","author":"Pol","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/apt.12538-BIB0074|apt12538-cit-0074","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2007.02.040","article-title":"Navigating the maze of hepatitis B treatments","volume":"132","author":"Lok","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.12538-BIB0075|apt12538-cit-0075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","article-title":"Prophylaxis and treatment of hepatitis B in immunocompromised patients","volume":"39","author":"Marzano","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1111\/apt.12538-BIB0076|apt12538-cit-0076","first-page":"S1","article-title":"KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"109","author":"KDIGO","year":"2008","journal-title":"Kidney Int Suppl"},{"key":"10.1111\/apt.12538-BIB0077|apt12538-cit-0077","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.RVI.0000109403.52762.C4","article-title":"Transjugular liver biopsy in patients with end-stage renal disease","volume":"15","author":"Ahmad","year":"2004","journal-title":"J Vasc Interv Radiol"},{"issue":"Suppl 3","key":"10.1111\/apt.12538-BIB0078|apt12538-cit-0078","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kasiske","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/apt.12538-BIB0079|apt12538-cit-0079","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2125.1998.00044.x","article-title":"Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis","volume":"46","author":"Johnson","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/apt.12538-BIB0080|apt12538-cit-0080","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2165\/00003088-200645110-00005","article-title":"Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment","volume":"45","author":"Kearney","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/apt.12538-BIB0081|apt12538-cit-0081","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1177\/0091270010381385","article-title":"Efficacy and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Renal Impairment","volume":"51","author":"Shiffman","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/apt.12538-BIB0082|apt12538-cit-0082","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2125.2007.02963.x","article-title":"Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure","volume":"64","author":"Asari","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/apt.12538-BIB0083|apt12538-cit-0083","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1111\/j.1572-0241.2000.03296.x","article-title":"An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation","volume":"95","author":"Ben-Ari","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/apt.12538-BIB0084|apt12538-cit-0084","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0041-1345(02)02879-8","article-title":"Lamivudine in renal transplant candidates with chronic hepatitis B infection","volume":"34","author":"Boyacioglu","year":"2002","journal-title":"Transplant Proc"},{"key":"10.1111\/apt.12538-BIB0085|apt12538-cit-0085","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1097\/00007890-200005270-00020","article-title":"HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients","volume":"69","author":"Fontaine","year":"2000","journal-title":"Transplantation"},{"key":"10.1111\/apt.12538-BIB0086|apt12538-cit-0086","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3748\/wjg.v11.i3.400","article-title":"Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation","volume":"11","author":"Lapinski","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1111\/apt.12538-BIB0087|apt12538-cit-0087","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00004836-200307000-00016","article-title":"Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection","volume":"37","author":"Schmilovitz-Weiss","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/apt.12538-BIB0088|apt12538-cit-0088","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/01.tp.0000178305.39231.a2","article-title":"Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency","volume":"80","author":"Fontaine","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/apt.12538-BIB0089|apt12538-cit-0089","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1016\/j.transproceed.2005.09.123","article-title":"Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection","volume":"37","author":"Gornals","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/apt.12538-BIB0090|apt12538-cit-0090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1053\/jlts.2003.50010","article-title":"Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency","volume":"9","author":"Tillmann","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1111\/apt.12538-BIB0091|apt12538-cit-0091","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/dat.20485","article-title":"Entecavir in the treatment of chronic hepatitis B in end stage renal disease and kidney transplantation","volume":"39","author":"Ridruejo","year":"2010","journal-title":"Dial Transplant"},{"key":"10.1111\/apt.12538-BIB0092|apt12538-cit-0092","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/ndt\/gfg327","article-title":"Pharmacokinetics of tenofovir in haemodialysis","volume":"18","author":"Izzedine","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/apt.12538-BIB0093|apt12538-cit-0093","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1111\/j.1600-6143.2005.01113.x","article-title":"HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/apt.12538-BIB0094|apt12538-cit-0094","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00007890-199607270-00025","article-title":"The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection","volume":"62","author":"Fornairon","year":"1996","journal-title":"Transplantation"},{"key":"10.1111\/apt.12538-BIB0095|apt12538-cit-0095","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.transproceed.2009.01.074","article-title":"Impact of hepatitis B and C virus infections on kidney transplantation: a single center experience","volume":"41","author":"Santos","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1111\/apt.12538-BIB0096|apt12538-cit-0096","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/jhep.2002.36156","article-title":"Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients","volume":"36","author":"Chan","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/apt.12538-BIB0097|apt12538-cit-0097","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1525-139X.2010.00809.x","article-title":"Evaluation of adult kidney transplant candidates","volume":"23","author":"Pham","year":"2010","journal-title":"Semin Dial"},{"key":"10.1111\/apt.12538-BIB0098|apt12538-cit-0098","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1034\/j.1600-6143.2003.30113.x","article-title":"Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy","volume":"3","author":"Baid","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1111\/apt.12538-BIB0099|apt12538-cit-0099","first-page":"280","volume-title":"Handbook of Kidney Transplantation","author":"Fabrizi","year":"2010"},{"key":"10.1111\/apt.12538-BIB0100|apt12538-cit-0100","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10157-011-0477-2","article-title":"Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection","volume":"15","author":"Numata","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"10.1111\/apt.12538-BIB0101|apt12538-cit-0101","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/sj.ki.5001908","article-title":"Hepatitis B treatment: lessons for the nephrologist","volume":"70","author":"Olsen","year":"2006","journal-title":"Kidney Int"},{"key":"10.1111\/apt.12538-BIB0102|apt12538-cit-0102","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.TP.0000116448.97841.6D","article-title":"Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials","volume":"77","author":"Fabrizi","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/apt.12538-BIB0103|apt12538-cit-0103","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5414\/CNP71036","article-title":"Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients","volume":"71","author":"Kamar","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1111\/apt.12538-BIB0104|apt12538-cit-0104","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1016\/j.transproceed.2006.08.186","article-title":"Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results","volume":"38","author":"Silva","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1111\/apt.12538-BIB0105|apt12538-cit-0105","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.transproceed.2005.02.010","article-title":"Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection","volume":"37","author":"Garcia","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/apt.12538-BIB0106|apt12538-cit-0106","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1399-0012.2009.01090.x","article-title":"Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B","volume":"24","author":"Tse","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1111\/apt.12538-BIB0107|apt12538-cit-0107","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/ndt\/gfr174","article-title":"Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B","volume":"26","author":"Lampertico","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/apt.12538-BIB0108|apt12538-cit-0108","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/TP.0b013e3181806c8c","article-title":"Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients","volume":"86","author":"Kamar","year":"2008","journal-title":"Transplantation"},{"key":"10.1111\/apt.12538-BIB0109|apt12538-cit-0109","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/TP.0b013e3181e5b811","article-title":"Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments","volume":"90","author":"Yap","year":"2010","journal-title":"Transplantation"},{"key":"10.1111\/apt.12538-BIB0110|apt12538-cit-0110","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/TP.0b013e3182100f59","article-title":"Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients","volume":"91","author":"Daude","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/apt.12538-BIB0111|apt12538-cit-0111","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1399-0012.2005.00350.x","article-title":"Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation","volume":"19","author":"Akalin","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1111\/apt.12538-BIB0112|apt12538-cit-0112","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/01.tp.0000189930.89031.1b","article-title":"Kidney transplantation from anti-HBc+ donors: results from a retrospective Italian study","volume":"81","author":"Feo","year":"2006","journal-title":"Transplantation"},{"key":"10.1111\/apt.12538-BIB0113|apt12538-cit-0113","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1016\/j.transproceed.2005.06.068","article-title":"Use of hepatitis B core antibody-positive donor kidneys in hepatitis B surface antibody-positive and -negative recipients","volume":"37","author":"Veroux","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/apt.12538-BIB0114|apt12538-cit-0114","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/j.1600-6143.2009.02707.x","article-title":"Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center","volume":"9","author":"Jiang","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/apt.12538-BIB0115|apt12538-cit-0115","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1016\/j.transproceed.2005.10.094","article-title":"The effect of HBsAg-positivity of kidney donors on long-term patient and graft outcome","volume":"37","author":"Berber","year":"2005","journal-title":"Transplant Proc"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12538","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/apt.12538\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T00:01:36Z","timestamp":1716076896000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,29]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"URL":"https:\/\/doi.org\/10.1111\/apt.12538","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10,29]]}}}